Journal of Oral Pathology and Medicine · 2013 · 39 citations · 27 references
MedicineOncologyPharmacologyCancer PharmacologyMetastasisMolecular OncologyCancer Cell SignalingCancer ProgressionInvasion In Oral CancerMalignant NeoplasmsSquamous Cell CarcinomaTargeted Cancer TherapyCetuximab TherapyChimeric Monoclonal AntibodiesEgfr InhibitionEpidermal Growth Factor Receptor InhibitionEpithelial-mesenchymal Transition In CancerIntegrin Signaling In CancerUbiquitin-proteasome ProteolysisUbiquitin-proteasome Signaling
Cetuximab (Erbitux, C225) is a chimeric monoclonal antibody that binds to the extracellular domain of epidermal growth factor receptor (EGFR), inhibiting tumor growth, invasion, angiogenesis and metastasis. However, the mechanisms underlying the effect of Cetuximab in human oral squamous cell carcinoma (OSCC) remain unclear. Here, we report that Cetuximab modulates EGFR protein stability through the ubiquitin/proteasome pathway, resulting in the inhibition of human OSCC growth. Cetuximab significantly inhibited the migration and invasion of human OSCC cells by blocking epithelial/mesenchymal transition (EMT) and the AKT and ERK pathways. Furthermore, Cetuximab-inhibited cell growth by modulating the expression of integrin β5. Taken together, these results provide novel insights into the mechanism of Cetuximab action and suggest potential therapeutic strategies for OSCC.
27
James A. Bonner, Paul M. Harari, J. Giralt et al. · The Lancet Oncology · 2009 · 2K citations
Zhimin Lu, Guoqiang Jiang, Peter Blume‐Jensen et al. · Molecular and Cellular Biology · 2001 · 327 citations · Full text